AR097584A1 - Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano - Google Patents

Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano

Info

Publication number
AR097584A1
AR097584A1 ARP140103345A ARP140103345A AR097584A1 AR 097584 A1 AR097584 A1 AR 097584A1 AR P140103345 A ARP140103345 A AR P140103345A AR P140103345 A ARP140103345 A AR P140103345A AR 097584 A1 AR097584 A1 AR 097584A1
Authority
AR
Argentina
Prior art keywords
seq
chain variable
variable domain
heavy chain
light chain
Prior art date
Application number
ARP140103345A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR097584A1 publication Critical patent/AR097584A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)

Abstract

Reivindicación 1: Un anticuerpo, que se une al CSF-1R humano, donde dicho anticuerpo se administra en combinación con un anticuerpo, que se une al PD-L1 humano, para uso en el tratamiento del cáncer, para uso en la prevención o el tratamiento de metástasis, para uso en el tratamiento enfermedades inflamatorias, para uso en el tratamiento de pérdidas óseas, para uso en el tratamiento o retardo del progreso de una enfermedad de carácter inmune, por ejemplo la inmunidad tumoral o para uso en la estimulación de una respuesta o función inmune, por ejemplo la actividad de las células T, dicho el anticuerpo, que se une al CSF-1R humano, empleado en la terapia de combinación se caracteriza porque contiene a) un dominio variable de cadena pesada VH de SEQ ID Nº 23 y un dominio variable de cadena ligera VL de SEQ ID Nº 24 o b) un dominio variable de cadena pesada VH de SEQ ID Nº 31 y un dominio variable de cadena ligera VL de SEQ ID Nº 32 o c) un dominio variable de cadena pesada VH de SEQ ID Nº 39 y un dominio variable de cadena ligera VL de SEQ ID Nº 40 o d) un dominio variable de cadena pesada VH de SEQ ID Nº 47 y un dominio variable de cadena ligera VL de SEQ ID Nº 48 o e) un dominio variable de cadena pesada VH de SEQ ID Nº 55 y un dominio variable de cadena ligera VL de SEQ ID Nº 56; y el anticuerpo, que se une al PD-L1 humano empleado en la terapia de combinación se caracteriza porque contiene a) un dominio variable de cadena pesada VH de SEQ ID Nº 89 y un dominio variable de cadena ligera VL de SEQ ID Nº 92 o b) un dominio variable de cadena pesada VH de SEQ ID Nº 90 y un dominio variable de cadena ligera VL de SEQ ID Nº 93 o c) un dominio variable de cadena pesada VH de SEQ ID Nº 90 y un dominio variable de cadena ligera VL de SEQ ID Nº 94 o d) un dominio variable de cadena pesada VH de SEQ ID Nº 90 y un dominio variable de cadena ligera VL de SEQ ID Nº 95 o e) un dominio variable de cadena pesada VH de SEQ ID Nº 90 y un dominio variable de cadena ligera VL de SEQ ID Nº 96 o f) un dominio variable de cadena larga VH de SEQ ID Nº 90 y un dominio variable de cadena ligera VL de SEQ ID Nº 97 o g) un dominio variable de cadena pesada VH de SEQ ID Nº 90 y un dominio variable de cadena ligera VL de SEQ ID Nº 98 o h) un dominio variable de cadena pesada VH de SEQ ID Nº 90 y un dominio variable de cadena ligera VL de SEQ ID Nº 99 o i) un dominio variable de cadena pesada VH de SEQ ID Nº 90 y un dominio variable de cadena ligera VL de SEQ ID Nº 100 o j) un dominio variable de cadena pesada VH de SEQ ID Nº 90 y un dominio variable de cadena ligera VL de SEQ ID Nº 101 o k) un dominio variable de cadena pesada VH de SEQ ID Nº 90 y un dominio variable de cadena ligera VL de SEQ ID Nº 102 o l) un dominio variable de cadena pesada VH de SEQ ID Nº 90 y un dominio variable de cadena ligera VL de SEQ ID Nº 103 o m) un dominio variable de cadena pesada VH de SEQ ID Nº 90 y un dominio variable de cadena ligera VL de SEQ ID Nº 104 o n) un dominio variable de cadena pesada VH de SEQ ID Nº 90 y un dominio variable de cadena ligera VL de SEQ ID Nº 105 u o) un dominio variable de cadena pesada VH de SEQ ID Nº 90 y un dominio variable de cadena ligera VL de SEQ ID Nº 106 o p) un dominio variable de cadena pesada VH de SEQ ID Nº 91 y un dominio variable de cadena ligera VL de SEQ ID Nº 107. Reivindicación 3: El anticuerpo según la reivindicación 2, para uso en el tratamiento del cáncer de mama, el cáncer de pulmón, el cáncer de colon, el cáncer de ovarios, el cáncer de tipo melanoma, el cáncer de vejiga, el cáncer renal, el cáncer de riñón, el cáncer de hígado, el cáncer de cabeza y cuello, el cáncer colorrectal, el cáncer de páncreas, el carcinoma gástrico, el cáncer de esófago, el mesotelioma, el cáncer de próstata, la leucemia, los linfomas, los mielomas.
ARP140103345A 2013-09-12 2014-09-08 Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano AR097584A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13184120 2013-09-12

Publications (1)

Publication Number Publication Date
AR097584A1 true AR097584A1 (es) 2016-03-23

Family

ID=49123797

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140103345A AR097584A1 (es) 2013-09-12 2014-09-08 Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano

Country Status (16)

Country Link
US (4) US20150073129A1 (es)
EP (1) EP3044235B1 (es)
JP (2) JP6526681B2 (es)
KR (1) KR20160035090A (es)
CN (2) CN105473617A (es)
AR (1) AR097584A1 (es)
AU (1) AU2014320355A1 (es)
BR (1) BR112016000903A2 (es)
CA (1) CA2916826A1 (es)
HK (1) HK1217021A1 (es)
IL (1) IL243348A0 (es)
MX (1) MX2016003129A (es)
RU (1) RU2016113757A (es)
SG (1) SG11201601881RA (es)
TW (1) TWI617579B (es)
WO (1) WO2015036511A1 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2510010T3 (pl) 2009-12-10 2016-05-31 Hoffmann La Roche Przeciwciała wiążące zewnątrzkomórkową domenę 4 ludzkiego CSF1R i ich zastosowanie
CN102918060B (zh) 2010-03-05 2016-04-06 霍夫曼-拉罗奇有限公司 抗人csf-1r抗体及其用途
RU2617966C2 (ru) 2010-03-05 2017-04-28 Ф.Хоффманн-Ля Рош Аг Антитела против csf-1r человека и их применение
JP6242804B2 (ja) 2011-12-15 2017-12-06 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ヒトｃｓｆ−１ｒに対する抗体及びその使用
AR095882A1 (es) 2013-04-22 2015-11-18 Hoffmann La Roche Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
AR097584A1 (es) 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
US10570204B2 (en) 2013-09-26 2020-02-25 The Medical College Of Wisconsin, Inc. Methods for treating hematologic cancers
EP3083686B2 (en) * 2013-12-17 2023-03-22 F. Hoffmann-La Roche AG Methods of treating cancers using pd-1 axis binding antagonists and taxanes
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
JP6681905B2 (ja) 2014-09-13 2020-04-15 ノバルティス アーゲー Ａｌｋ阻害剤の併用療法
CR20170143A (es) 2014-10-14 2017-06-19 Dana Farber Cancer Inst Inc Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
JP6920989B2 (ja) 2014-10-29 2021-08-18 ファイヴ プライム セラピューティクス インク がんのための併用療法
NZ733854A (en) 2015-02-26 2022-07-01 Merck Patent Gmbh Pd-1 / pd-l1 inhibitors for the treatment of cancer
WO2016149201A2 (en) 2015-03-13 2016-09-22 Cytomx Therapeutics, Inc. Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
PT3283527T (pt) 2015-04-13 2021-03-03 Five Prime Therapeutics Inc Terapêutica de combinação para o cancro
JP6876629B2 (ja) * 2015-06-16 2021-05-26 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Ｐｄ−ｌ１アンタゴニスト併用療法
WO2016205320A1 (en) 2015-06-17 2016-12-22 Genentech, Inc. Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes
EP3108897A1 (en) * 2015-06-24 2016-12-28 F. Hoffmann-La Roche AG Antibodies against human csf-1r for use in inducing lymphocytosis in lymphomas or leukemias
WO2016207312A1 (en) * 2015-06-24 2016-12-29 F. Hoffmann-La Roche Ag Antibodies against human csf-1r for use in inducing lymphocytosis in lymphomas or leukemias
BR112018000212A2 (pt) 2015-07-29 2018-09-04 Novartis Ag uso combinado de anticorpos anti pd-1 e anti m-csf no tratamento de câncer
PE20181322A1 (es) * 2015-09-01 2018-08-14 Agenus Inc Anticuerpo anti-pd1 y sus metodos de uso
RU2727914C2 (ru) 2015-11-17 2020-07-24 Сучжоу Санкадия Биофармасьютикалз Ко., Лтд. Антитело против лиганда 1 запрограммированной гибели клеток (pd-l1), его антигенсвязывающий фрагмент и их медицинское применение
CN108350080A (zh) * 2015-11-24 2018-07-31 伊莱利利公司 用于癌症的联合疗法
EP3400246B1 (en) 2016-01-08 2020-10-21 H. Hoffnabb-La Roche Ag Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies
JP7461741B2 (ja) 2016-06-20 2024-04-04 カイマブ・リミテッド 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
JP7138094B2 (ja) * 2016-08-25 2022-09-15 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト マクロファージ活性化剤と組み合わせた抗ｃｓｆ－１ｒ抗体の間欠投与
IL265762B2 (en) 2016-10-06 2024-04-01 Merck Patent Gmbh Dosing regimen of avelumab for the treatment of cancer
EP3558360A1 (en) * 2016-12-22 2019-10-30 F. Hoffmann-La Roche AG Treatment of tumors with an anti-csf-1r antibody in combination with an anti-pd-l1 antibody after failure of anti-pd-l1/pd1 treatment
WO2018144334A1 (en) * 2017-02-02 2018-08-09 Imclone Llc Dosing regimen for anti-csf-1r antibody
CA3057758A1 (en) * 2017-03-29 2018-10-04 Glycotope Gmbh Pd-l1 and ta-muc1 antibodies
AU2018256406A1 (en) 2017-04-19 2019-10-17 Marengo Therapeutics, Inc. Multispecific molecules and uses thereof
CA3059468A1 (en) * 2017-04-27 2018-11-01 Tesaro, Inc. Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof
CN110914302A (zh) 2017-06-01 2020-03-24 赛托姆克斯治疗学股份有限公司 可活化抗pdl1抗体及其使用方法
US11421034B2 (en) 2017-09-13 2022-08-23 Five Prime Therapeutics, Inc. Combination anti-CSF1R and anti-PD-1 antibody combination therapy for pancreatic cancer
JP7348899B2 (ja) * 2017-12-08 2023-09-21 マレンゴ・セラピューティクス，インコーポレーテッド 多重特異性分子及びその使用
JP2021510078A (ja) 2018-01-10 2021-04-15 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司Ｊｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．， Ｌｔｄ． Ｐｄ−ｌ１抗体、その抗原結合フラグメント、及びその製薬学的使用
AU2019256460A1 (en) * 2018-04-19 2020-11-12 The Board Of Trustees Of The University Of Illinois Methods and compositions of inhibiting CSF1R for treating allergic inflammation
CN110563842B (zh) * 2018-06-06 2022-07-29 浙江博锐生物制药有限公司 针对程序性死亡配体(pd-l1)的抗体及其应用
AU2019416117B2 (en) 2018-12-28 2024-05-02 Deciphera Pharmaceuticals, Llc CSF1R inhibitors for use in treating cancer
CN114225023B (zh) * 2021-12-22 2022-10-18 宝船生物医药科技(上海)有限公司 抗csf-1r抗体联合抗pd-l1抗体的应用
CN114380913B (zh) * 2022-03-24 2022-06-21 上海济煜医药科技有限公司 一种全人源抗pd-l1抗体及其应用

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US7405270B2 (en) 1991-10-25 2008-07-29 Immunex Corporation CD40-Ligand lacking native-pattern glycosylation
US5961974A (en) 1991-10-25 1999-10-05 Immunex Corporation Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same
US5981724A (en) 1991-10-25 1999-11-09 Immunex Corporation DNA encoding CD40 ligand, a cytokine that binds CD40
JPH08507916A (ja) 1992-06-09 1996-08-27 カイロン コーポレイション Ｍ−ｃｓｆの結晶化
NZ258392A (en) 1992-11-13 1997-09-22 Idec Pharma Corp Chimeric and radiolabelled antibodies to the b lymphocyte cellsurface antigen bp35 (cd-20) and their use in the treatment of b cell lymphona
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
UA40577C2 (uk) 1993-08-02 2001-08-15 Мерк Патент Гмбх Біспецифічна молекула, що використовується для лізису пухлинних клітин, спосіб її одержання, моноклональне антитіло (варіанти), фармацевтичний препарат, фармацевтичний набір (варіанти), спосіб видалення пухлинних клітин
US5571751A (en) 1994-05-09 1996-11-05 National Semiconductor Corporation Interconnect structures for integrated circuits
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
JPH0967400A (ja) 1995-08-31 1997-03-11 Toray Ind Inc モノクローナル抗体、該抗体を産生するハイブリドーマ及びその利用
WO1998043089A1 (en) 1997-03-03 1998-10-01 Bristol-Myers Squibb Company Monoclonal antibodies to human cd6
DE69833755T2 (de) 1997-05-21 2006-12-28 Biovation Ltd. Verfahren zur herstellung von nicht-immunogenen proteinen
ATE257392T1 (de) 1997-10-02 2004-01-15 Max Planck Gesellschaft Verfahren zur modulierung der neovaskularisierung und/oder des wachstums von kollateraler arterien und / oder anderer arterien aus bestehenden arteriolären verbindungen
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
DE19935756A1 (de) 1999-07-27 2001-02-08 Mologen Forschungs Entwicklung Kovalent geschlossenes Nukleinsäuremolekül zur Immunstimulation
WO2001030381A2 (de) 1999-10-28 2001-05-03 Hofbauer, Reinhold Verwendung von csf-1-inhibitoren
DE60031793T2 (de) 1999-12-29 2007-08-23 Immunogen Inc., Cambridge Doxorubicin- und daunorubicin-enthaltende, zytotoxische mittel und deren therapeutische anwendung
US7108852B2 (en) 2000-03-20 2006-09-19 Warner-Lambert Company Llc Methods of treating inflammation using antibodies to M-CSF
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
EP1572106B1 (en) 2002-11-15 2010-05-05 Novartis Vaccines and Diagnostics, Inc. Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
GB0325836D0 (en) 2003-11-05 2003-12-10 Celltech R&D Ltd Biological products
AU2004316290C1 (en) 2003-11-06 2012-02-02 Seagen Inc. Monomethylvaline compounds capable of conjugation to ligands
AU2005267062C1 (en) 2004-07-22 2013-01-17 Five Prime Therapeutics, Inc. Compositions and methods of use for MGD-CSF in disease treatment
EP1858928A2 (en) 2005-03-08 2007-11-28 Pharmacia & Upjohn Company LLC Anti-m-csf antibody compositions having reduced levels of endotoxin
CA2609269C (en) 2005-05-26 2014-08-05 Seattle Genetics, Inc. Humanized anti-cd40 antibodies and their methods of use
KR101804078B1 (ko) 2005-06-08 2017-12-01 다나-파버 캔서 인스티튜트 인크. 예정 세포사 1(ｐｄ-1) 경로를 억제함으로써 지속 감염 및 암을 치료하기 위한 방법 및 조성물
AU2006329944A1 (en) 2005-12-09 2007-07-05 Seattle Genetics, Inc. Methods of using CD40 binding agents
CN101534858A (zh) 2006-01-05 2009-09-16 诺华有限公司 预防和治疗癌症转移和癌症转移相关性骨丢失的方法
US20070280935A1 (en) 2006-04-07 2007-12-06 Bernd Bohrmann Antibody that recognizes phosphorylated peptides
CA2671883A1 (en) 2006-12-12 2008-06-19 Idera Pharmaceuticals, Inc. Synthetic agonists of tlr9
EP2079760B1 (en) 2006-12-27 2016-04-27 Emory University Compositions and methods for the treatment of infections
WO2008119493A1 (en) 2007-03-30 2008-10-09 F. Hoffmann-La Roche Ag Composition of labeled and non-labeled monoclonal antibodies
CN103694351A (zh) 2007-06-05 2014-04-02 耶鲁大学 受体酪氨酸激酶抑制剂及其使用方法
HUE037265T2 (hu) 2007-08-21 2018-08-28 Amgen Inc Humán c-fms antigént kötõ proteinek
US8470977B2 (en) 2008-03-14 2013-06-25 Transgene S.A. Antibody against the CSF-1R
RU2547586C2 (ru) 2008-03-14 2015-04-10 Трансжене С.А. Антитело против csf-1r
EP2271673B1 (en) 2008-03-26 2016-02-24 Cellerant Therapeutics, Inc. Cytokine receptors associated with myelogenous haematological proliferative disorders and uses thereof
PT2376535T (pt) 2008-12-09 2017-06-23 Hoffmann La Roche Anticorpos anti-pd-l1 e a sua utilização para a melhoria do funcionamento das células t
WO2010088395A2 (en) 2009-01-30 2010-08-05 Idera Pharmaceuticals, Inc. Novel synthetic agonists of tlr9
NZ595825A (en) 2009-04-20 2012-10-26 Kyowa Hakko Kirin Co Ltd Antibody containing igg2 having amino acid mutation introduced therein
SMT202000195T1 (it) * 2009-11-24 2020-05-08 Medimmune Ltd Agenti leganti direzionati contro b7-h1
PL2510010T3 (pl) 2009-12-10 2016-05-31 Hoffmann La Roche Przeciwciała wiążące zewnątrzkomórkową domenę 4 ludzkiego CSF1R i ich zastosowanie
CN102918060B (zh) 2010-03-05 2016-04-06 霍夫曼-拉罗奇有限公司 抗人csf-1r抗体及其用途
RU2617966C2 (ru) 2010-03-05 2017-04-28 Ф.Хоффманн-Ля Рош Аг Антитела против csf-1r человека и их применение
AR080794A1 (es) 2010-03-26 2012-05-09 Hoffmann La Roche Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2
AR080698A1 (es) 2010-04-01 2012-05-02 Imclone Llc Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
EP3943154A1 (en) * 2010-05-04 2022-01-26 Five Prime Therapeutics, Inc. Antibodies that bind csf1r
JP5798404B2 (ja) 2010-08-31 2015-10-21 日東電工株式会社 極板保護用粘着テープ
WO2012068470A2 (en) 2010-11-19 2012-05-24 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response
GB201021867D0 (en) 2010-12-23 2011-02-02 Mologen Ag Non-coding immunomodulatory DNA construct
DK2691417T4 (en) 2011-03-29 2025-01-02 Roche Glycart Ag Antistof fc-varianter
FR2975600B1 (fr) 2011-05-24 2013-07-05 Assist Publ Hopitaux De Paris Agents pour le traitement de tumeurs
EP2734547B1 (en) 2011-07-18 2016-12-21 The University of Melbourne Use of c-fms antagonists
UA117220C2 (uk) 2011-08-01 2018-07-10 Дженентек, Інк. Способи лікування раку з використанням антагоністів, що зв'язуються з віссю pd-1, і інгібіторів mek
CA2851771C (en) 2011-10-21 2018-09-11 Transgene Sa Modulation of macrophage activation
HUE051954T2 (hu) * 2011-11-28 2021-03-29 Merck Patent Gmbh ANTI-PD-L1 ellenanyagok és alkalmazásaik
JP6242804B2 (ja) 2011-12-15 2017-12-06 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ヒトｃｓｆ−１ｒに対する抗体及びその使用
KR20140127855A (ko) 2012-02-06 2014-11-04 제넨테크, 인크. Csf1r 억제제를 사용하는 조성물 및 방법
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
US8993614B2 (en) 2012-03-15 2015-03-31 F. Hoffmann-La Roche Ag Substituted pyrrolidine-2-carboxamides
JP2015517490A (ja) 2012-05-11 2015-06-22 ファイブ プライム セラピューティックス インコーポレイテッド コロニー刺激因子１受容体（ｃｓｆ１ｒ）を結合させる抗体を用いて状態を治療する方法
US20130302322A1 (en) 2012-05-11 2013-11-14 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
US20140079699A1 (en) 2012-08-31 2014-03-20 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
WO2014072441A1 (en) 2012-11-09 2014-05-15 Transgene Sa Modulation of monocytes, or precursors thereof, differentiation
AR095882A1 (es) 2013-04-22 2015-11-18 Hoffmann La Roche Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
AR097584A1 (es) 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
EP2963764A1 (en) 2014-07-02 2016-01-06 Delphi Technologies, Inc. Apparatus to provide reverse polarity protection
ES2725463T3 (es) 2014-08-12 2019-09-24 Alligator Bioscience Ab Tratamientos combinados con anticuerpos anti-CD40
JP6920989B2 (ja) 2014-10-29 2021-08-18 ファイヴ プライム セラピューティクス インク がんのための併用療法
CA2967368A1 (en) 2014-11-17 2016-05-26 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
NZ771297A (en) 2014-12-31 2024-11-29 Checkmate Pharmaceuticals Inc Combination tumor immunotherapy
TW201717935A (zh) 2015-06-03 2017-06-01 波士頓生醫公司 用於治療癌症的組成物和方法
JP7138094B2 (ja) 2016-08-25 2022-09-15 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト マクロファージ活性化剤と組み合わせた抗ｃｓｆ－１ｒ抗体の間欠投与
EP3558360A1 (en) 2016-12-22 2019-10-30 F. Hoffmann-La Roche AG Treatment of tumors with an anti-csf-1r antibody in combination with an anti-pd-l1 antibody after failure of anti-pd-l1/pd1 treatment
JP2020510673A (ja) 2017-03-03 2020-04-09 ヤンセン バイオテツク，インコーポレーテツド がんの治療のための低分子ｃｓｆ−１ｒ阻害剤とｃｄ４０に特異的に結合するアゴニスト抗体とを含む併用療法
US11078283B2 (en) 2018-01-17 2021-08-03 Apexigen, Inc. Anti-PD-L1 antibodies and methods of use
KR20210062027A (ko) 2018-09-13 2021-05-28 에프. 호프만-라 로슈 아게 Csf-1r 항체 제제

Also Published As

Publication number Publication date
US20180346581A1 (en) 2018-12-06
EP3044235B1 (en) 2020-09-02
TW201522376A (zh) 2015-06-16
MX2016003129A (es) 2016-08-08
JP2016531150A (ja) 2016-10-06
JP6526681B2 (ja) 2019-06-05
SG11201601881RA (en) 2016-04-28
US20200392234A1 (en) 2020-12-17
CN105473617A (zh) 2016-04-06
AU2014320355A1 (en) 2016-02-18
US20150073129A1 (en) 2015-03-12
TWI617579B (zh) 2018-03-11
RU2016113757A (ru) 2017-10-17
JP2019001789A (ja) 2019-01-10
US11512133B2 (en) 2022-11-29
WO2015036511A1 (en) 2015-03-19
US20170051065A1 (en) 2017-02-23
HK1217021A1 (zh) 2016-12-16
BR112016000903A2 (pt) 2017-12-12
KR20160035090A (ko) 2016-03-30
CN119303076A (zh) 2025-01-14
CA2916826A1 (en) 2015-03-19
EP3044235A1 (en) 2016-07-20
IL243348A0 (en) 2016-03-31

Similar Documents

Publication Publication Date Title
AR097584A1 (es) Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
HRP20200272T1 (hr) Kombinirana terapija za imunocitokine varijante il-2 usmjerene na tumor i protutijela protiv humanog pd-l1
PH12017501728A1 (en) Chimeric antigen receptors targeting b-cell maturation antigen
CL2018001722A1 (es) Nuevos anticuerpos anti-mfi2 y métodos de uso (divisional solicitud 201700506)
EA201890294A1 (ru) Химерный полипептидный комплекс и способы его получения и применения
MX2021003704A (es) Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales.
MX2019006598A (es) Celulas asesinas naturales modificadas geneticamente y sus usos.
EA201890131A1 (ru) Иммуномодуляция и лечение солидных опухолей антителами, которые специфически связывают cd38
UY36862A (es) Conjugados anticuerpo anti-dll3-fármaco y métodos de uso
GT201700067A (es) Compuestos de aminopiridiloxipirazol
CL2017000885A1 (es) Anticuerpos anti-ox40 humanizados y usos de los mismos
PE20181066A1 (es) Diacuerpos monovalentes biespecificos que son capaces de unirse a b7-h3 y cd3, y usos de los mismos
EA201892294A1 (ru) Антитела и композиции против tim-3
PH12019502637A1 (en) Chimeric antigen receptors targeting flt3
EA201792589A1 (ru) Антитела против cd123 и конъюгаты указанных антител
CO2020013089A2 (es) Anticuerpos contra mica y/o micb y sus usos
EA201692100A1 (ru) Новые антитела против rnf43 и способы их применения
EA201790799A1 (ru) Композиции и способы для применения для усиления иммунного ответа и терапии злокачественных опухолей
MX2016015614A (es) Anticuerpos anti proteína relacionada con el receptor del factor de necrosis tumoral inducida por glucocorticóides (gitr) y sus métodos de uso.
PE20171383A1 (es) Receptores de antigeno quimericos anti-dll3 y metodos de uso
PE20161389A1 (es) Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblastica aguda
MX2013011742A (es) Inversion de los efectos del micro-ambiente de tumor utilizando receptores de citocina quimericos.
PE20171060A1 (es) Receptores quimericos de antigeno anti-cldn y metodos de uso
CY1123593T1 (el) Συνδυαστικη θεραπεια που περιλαμβανει αντισωματα κλωντινης 18.2 για τη θεραπεια του καρκινου
EA201792612A1 (ru) 6-аминохинолин-3-карбонитрилы в качестве модуляторов cot

Legal Events

Date Code Title Description
FB Suspension of granting procedure